newsFTC investigates contracts regarding autoimmune disease drug, Remicade1 August 2019 | By European Pharmaceutical ReviewThe US Federal Trade Commission is investigating whether Johnson and Johnson violated antitrust laws with its medication, Remicade.
newsBritish Columbia first province to switch patients to biosimilars30 May 2019 | By European Pharmaceutical ReviewBritish Columbia has said it will switch as many as 20,400 patients from three branded biologic drugs to cheap biosimilars.
newsEMA to review Sandoz biosimilars adalimumab and infliximab2 June 2017 | By Niamh Marriott (European Pharmaceutical Review)Sandoz announced that the EMA has accepted for regulatory review for biosimilars to AbbVie's Humira (adalimumab) and Janssen's Remicade (infliximab)...
newsStudy finds biosimilar switching not suitable for all patients10 June 2016 | By Victoria White, Digital Content ProducerA study presented at EULAR showed that when antibodies develop in response to the infliximab, they also cross-react with the biosimilar of infliximab...
newsInfliximab biosimilar Flixabi approved in the EU31 May 2016 | By Victoria White, Digital Content ProducerThe EC has granted marketing authorisation in the European Union (EU) for Flixabi, an infliximab biosimilar referencing Remicade...
newsInfliximab launch is milestone in development of UK biosimilars industry25 February 2015 | By British Generic Manufacturers AssociationThe onset of biosimilar competition in the UK in Infliximab is another significant milestone in the development of the sector in this country according to the British Generic Manufacturers Association (BGMA).
